vs
Side-by-side financial comparison of PATHWARD FINANCIAL, INC. (CASH) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
PATHWARD FINANCIAL, INC. is the larger business by last-quarter revenue ($173.1M vs $103.7M, roughly 1.7× Twist Bioscience Corp). PATHWARD FINANCIAL, INC. runs the higher net margin — 20.3% vs -29.4%, a 49.7% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -0.2%). PATHWARD FINANCIAL, INC. produced more free cash flow last quarter ($104.1M vs $-34.8M).
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
CASH vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $173.1M | $103.7M |
| Net Profit | $35.2M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 24.6% | -31.7% |
| Net Margin | 20.3% | -29.4% |
| Revenue YoY | -0.2% | 16.9% |
| Net Profit YoY | 11.9% | 3.4% |
| EPS (diluted) | $1.57 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $173.1M | $103.7M | ||
| Q3 25 | $186.7M | — | ||
| Q2 25 | $195.8M | — | ||
| Q1 25 | $274.8M | — | ||
| Q4 24 | $182.6M | — | ||
| Q3 24 | $179.5M | — | ||
| Q2 24 | $188.6M | — | ||
| Q1 24 | $257.6M | — |
| Q4 25 | $35.2M | $-30.5M | ||
| Q3 25 | $38.8M | — | ||
| Q2 25 | $42.1M | — | ||
| Q1 25 | $75.0M | — | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $33.5M | — | ||
| Q2 24 | $44.9M | — | ||
| Q1 24 | $69.9M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 24.6% | -31.7% | ||
| Q3 25 | 25.9% | — | ||
| Q2 25 | 24.1% | — | ||
| Q1 25 | 33.2% | — | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.9% | — | ||
| Q2 24 | 27.1% | — | ||
| Q1 24 | 33.8% | — |
| Q4 25 | 20.3% | -29.4% | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 21.5% | — | ||
| Q1 25 | 27.3% | — | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 18.7% | — | ||
| Q2 24 | 23.8% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | $1.57 | $-0.50 | ||
| Q3 25 | $1.69 | — | ||
| Q2 25 | $1.81 | — | ||
| Q1 25 | $3.14 | — | ||
| Q4 24 | $1.23 | — | ||
| Q3 24 | $1.34 | — | ||
| Q2 24 | $1.78 | — | ||
| Q1 24 | $2.74 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $331.2M | $197.9M |
| Total DebtLower is stronger | $33.5M | — |
| Stockholders' EquityBook value | $854.5M | $456.1M |
| Total Assets | $7.6B | $638.1M |
| Debt / EquityLower = less leverage | 0.04× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $331.2M | $197.9M | ||
| Q3 25 | $120.6M | — | ||
| Q2 25 | $258.3M | — | ||
| Q1 25 | $254.2M | — | ||
| Q4 24 | $597.4M | — | ||
| Q3 24 | $158.3M | — | ||
| Q2 24 | $298.9M | — | ||
| Q1 24 | $347.9M | — |
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $33.4M | — |
| Q4 25 | $854.5M | $456.1M | ||
| Q3 25 | $858.0M | — | ||
| Q2 25 | $819.0M | — | ||
| Q1 25 | $814.7M | — | ||
| Q4 24 | $758.3M | — | ||
| Q3 24 | $822.5M | — | ||
| Q2 24 | $748.4M | — | ||
| Q1 24 | $719.5M | — |
| Q4 25 | $7.6B | $638.1M | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $7.2B | — | ||
| Q1 25 | $7.0B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.5B | — | ||
| Q2 24 | $7.5B | — | ||
| Q1 24 | $7.4B | — |
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.05× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.3M | $-24.8M |
| Free Cash FlowOCF − Capex | $104.1M | $-34.8M |
| FCF MarginFCF / Revenue | 60.1% | -33.5% |
| Capex IntensityCapex / Revenue | 2.4% | 9.6% |
| Cash ConversionOCF / Net Profit | 3.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | $616.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.3M | $-24.8M | ||
| Q3 25 | $303.7M | — | ||
| Q2 25 | $30.4M | — | ||
| Q1 25 | $188.3M | — | ||
| Q4 24 | $-71.7M | — | ||
| Q3 24 | $143.1M | — | ||
| Q2 24 | $113.2M | — | ||
| Q1 24 | $203.0M | — |
| Q4 25 | $104.1M | $-34.8M | ||
| Q3 25 | $300.3M | — | ||
| Q2 25 | $27.7M | — | ||
| Q1 25 | $184.7M | — | ||
| Q4 24 | $-73.8M | — | ||
| Q3 24 | $138.8M | — | ||
| Q2 24 | $111.0M | — | ||
| Q1 24 | $201.3M | — |
| Q4 25 | 60.1% | -33.5% | ||
| Q3 25 | 160.9% | — | ||
| Q2 25 | 14.1% | — | ||
| Q1 25 | 67.2% | — | ||
| Q4 24 | -40.4% | — | ||
| Q3 24 | 77.3% | — | ||
| Q2 24 | 58.8% | — | ||
| Q1 24 | 78.1% | — |
| Q4 25 | 2.4% | 9.6% | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | — | ||
| Q1 24 | 2.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASH
| Consumer | $103.0M | 59% |
| Payment Card And Deposit Fees | $30.1M | 17% |
| Other | $24.2M | 14% |
| Rental Income | $11.6M | 7% |
| Commercial | $4.2M | 2% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
